A September 23, 2010 article in the New England Journal of Medicine announced that, finally, the FDA has stepped forward and decided on regulatory action for Avandia, a diabetes drug that last year claimed 1,354 lives as a result of cardiac-associated problems.
Under the ruling, the drug will be available to patients not already taking it only if they are unable to achieve glycemic control using other medications and, in consultation with their health care professional, decide not to take a different drug for medical reasons.
Current users of Avandia will be able to continue using the medication if they appear to be benefiting from it and they acknowledge that they understand these risks. Doctors will have to attest to and document their patients’ eligibility; patients will have to review statements describing the cardiovascular safety concerns.
But did the FDA go far enough – could it be too little, too late?
One morning early last July, Micha Bitsinnie arrived at work to an onslaught of messages from...
Authorities in France have placed more than a third of the country under a red heat...
An influenza outbreak has reportedly sickened more than 150 recruits in training at Lackland air force...
